A large VHA real-world analysis compared GLP‑1 receptor agonists (~132,000) with sulfonylureas (>201,000), focusing on major adverse cardiovascular outcomes in type 2 diabetes. Continuous GLP‑1 ...
One major benefit of taking injected GLP-1 medications is a sizeable reduction in risk for heart attacks, strokes and other heart problems. However, if people stop taking the medication, those heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results